Abbott Labs has three main business divisions (prescription drugs, nutritionals, and medical device) that are largely unrelated. During Abbott's last conference call, Jami Rubin, a drug analyst at Goldman Sachs argued that Abbott's stock is currently undervalued and could surge by 30% or more should management decide in favor of a company's breakup. The break-up theme was then re-examined in an issue of Barron's, published on February 12th, 2011. Management does not seem to favor the break-up strategy at this junction.
via seekingalpha.com
No comments:
Post a Comment